Tumor biomarkers predict clinical outcome of COVID-19 patients
Authors:
- 3 June 2020
- journal article
- letter
- Published by Elsevier in Journal of Infection
- Vol. 81 (3) , 452-482
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysisJournal of Infection, 2020
- Estimates of the severity of coronavirus disease 2019: a model-based analysisThe Lancet Infectious Diseases, 2020
- Kidney disease is associated with in-hospital death of patients with COVID-19Kidney International, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?Disease Markers, 2018
- Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosisRespirology, 2012
- Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.2008
- Evaluation of Cytokeratin 19 Serum Fragments (Cyfra 21–1) in Patients with Lung Cancer: Results of a Multicenter TrialThe International Journal of Biological Markers, 1994